New testing and treatment for MGUS, SMM, and MM

There are new studies being conducted at Dana Farber Institute for early detection and treatment of MGUS, SMM, and MM. Has anyone looked into this further? The blood test is called SWIFT-seq, and the treatment is called Allogeneic (non-autologous) CAR T-cell therapies.

SWIFT-seq is a novel single-cell sequencing blood test that can detect and analyze circulating tumor cells (CTCs) in conditions like MGUS (Monoclonal Gammopathy of Undetermined Significance), smoldering multiple myeloma (SMM), and multiple myeloma (MM). By providing a detailed molecular profile from a small number of cells in a blood sample, it can be used for comprehensive diagnostics, risk stratification, and monitoring, potentially reducing the need for invasive bone marrow biopsies.

About SWIFT-seq and MGUS
What SWIFT-seq does: It uses single-cell RNA sequencing to identify and profile CTCs in the blood. Unlike traditional methods that rely on cell surface markers, SWIFT-seq focuses on the cells' molecular barcodes.
How it works: It can analyze as few as 10 cells from a blood sample to provide a wealth of information, including the number of CTCs, their gene expression, and even cytogenetic information. This information can be used to infer things like translocation and copy number abnormalities.
Benefits:
• Minimally invasive: It provides a less invasive alternative to bone marrow biopsies.
• Comprehensive: It consolidates multiple tests (like those for tumor burden, genetic profile, and proliferative index) into a single blood test.
• Detailed insights: It can identify a gene signature that might be associated with tumor spread and can be used for risk stratification and monitoring.
• Application to MGUS: A study showed that SWIFT-seq could capture CTCs in 90% of patients with MGUS, SMM, or MM. Because MGUS is a precursor condition to MM, finding and analyzing these rare cells is key to understanding how the disease might progress.
https://www.dana-farber.org/newsroom/news-releases/2025/dana-farber-cancer-institute-unveils-groundbreaking-blood-test-for-multiple-myeloma